A blow for Alzheimer’s with committee voting against potential treatment

Another potential blow to the development of new treatments for Alzheimer’s disease with a US FDA expert advisory committee voting that trial data does not provide enough evidence to demonstrate the efficacy of Biogen's aducanumab. …